Latest Health News
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Achieved 100% ORR and 83.3% CR rate at dose level 2 following…
KFSH Highlights Human-Centered AI as a Path to Better Care at HLTH Europe 2026
RIYADH, Saudi Arabia, June 14, 2026 (GLOBE NEWSWIRE) -- At HLTH Europe…
Phase 3 Data Show TransCon PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
June 13, 2026 16:00 ET | Source: Ascendis Pharma Multi-organ system and…
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful…
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
June 13, 2026 07:30 ET | Source: Intellia Therapeutics, Inc. Data from…
New TALVEY(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma
TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and…
KFSH Highlights the Strategic Value of Tertiary Care AI Datasets in Advancing Precision Medicine and Clinical Innovation
RIYADH, Saudi Arabia, June 12, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist…
Protext Mobility Inc. (OTCID: TXTM) Unveils New Corporate Website and Investor Relations Platform to Support Strategic Growth and Exchange Uplisting
ENGINEERING THE INFRASTRUCTURE LAYER BETWEEN BIOLOGY, PHARMACEUTICAL SCIENCE & DIGITAL CAPITAL FORT…
Cosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit
Strong sales momentum: across the UK and Greece, the brands' first two…
